"At this moment, there is a massive effort to better understand the natural history of Alzheimer’s Disease (AD), as well to improve its management. These efforts wish to increase the chances of success for future clinical trials by allowing them to target populations at the early stages of the disease, when the damage could still be reversed. AMYPAD comes to provide valuable insight on a fundamental piece of the AD puzzle: the accumulation of β-amyloid plaques. We will be doing so by determining the role and value of amyloid imaging in disease diagnosis, prognosis, and potential for treatment monitoring - which will be a crucial step forward in the global fight against AD.” Frederik Barkhof

"AMYPAD is an exciting consortium which kicked off late 2016 and brings together some of the top academic imaging specialists with pharma partners. All are committed to the timely diagnosis and treatment of patients with dementia and we look forward to generating data over the next 4-5 years which could influence the time course of diagnosis and the possibility for therapeutic intervention at an earlier stage in the dementia spectrum." Gill Farrar